이트로시노니드
Itrocinonide![]() | |
임상자료 | |
---|---|
기타 이름 | D5159; 6α,9α-Difluoro-11β,16α,17α-trihydroxy-21-oxa-3-oxoandrosta-1,4-diene-17β-carboxylic acid, ester with ethyl (S)-1-hydroxyethyl carbonate, cyclic (R)-16,17-acetal with butyraldehyde; 6α,9α-Difluoro-11β,16α,17α-trihydroxy-21-oxapregna-1,4-diene-3,20-dione 21-(1-[(ethoxycarbonyl)oxy]ethyl), cyclic (R)-16,17-acetal with butyraldehyde |
마약류 | 코르티코스테로이드; 글루코코르티코이드 |
식별자 | |
| |
CAS 번호 | |
펍켐 CID | |
켐스파이더 | |
유니 | |
켐벨 | |
CompTox 대시보드 (EPA) | |
화학 및 물리적 데이터 | |
공식 | C29H38F2O9 |
어금질량 | 568.611 g·190−1 |
3D 모델(JSmol) | |
| |
|
Itrocinonide(개발 코드명 D5159)는 합성 글루코르티코이드 코르티코스테로이드로, 시판되지 않았다.[1][2][3]
참조
- ^ Bodor N, Buchwald P (29 August 2012). Retrometabolic Drug Design and Targeting. John Wiley & Sons. pp. 193–. ISBN 978-1-118-40776-9.
- ^ Schleimer RP (19 April 2016). Inhaled Steroids in Asthma: Optimizing Effects in the Airways. CRC Press. pp. 526–. ISBN 978-0-203-90853-2.
- ^ Hansel TT, Barnes PJ (1 January 2001). New Drugs for Asthma, Allergy and COPD. Karger Medical and Scientific Publishers. pp. 95–. ISBN 978-3-8055-6862-3.